Blue Light Cystoscopy: Indications and Outcomes.

Autor: Pohar KS; Department of Urology, The Ohio State University, Suite 3000, 915 Olentangy River Rd, Columbus, OH, 43212, USA. kamal.pohar@osumc.edu.
Jazyk: angličtina
Zdroj: Current urology reports [Curr Urol Rep] 2020 Apr 04; Vol. 21 (5), pp. 19. Date of Electronic Publication: 2020 Apr 04.
DOI: 10.1007/s11934-020-0966-5
Abstrakt: Purpose of Review: It has been firmly established that hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) reduces cancer recurrence rates. This review explores the impact of HAL-BLC on other meaningful outcomes in patients with bladder cancer, including disease progression, and earlier detection of disease at the time of surveillance cystoscopy.
Recent Findings: A randomized clinical trial confirmed earlier implementation of HAL-BLC at the time of surveillance cystoscopy increased identification of cancerous lesions, including those of high grade, when compared with white light cystoscopy. In addition, the evidence is evolving that the use of HAL-BLC at the time of endoscopic treatment of high-risk tumors may lead to lower rates of progression to muscle invasion, and this in part may be due to better risk stratification leading to changes in treatment plan. The clinical contexts for the use of HAL-BLC are broader than prior knowledge. It is also becoming more clear that the positive impact of HAL-BLC is likely more than just reducing cancer recurrence rates, and patients would benefit from the technology at many time points in the management and follow-up of their disease.
Databáze: MEDLINE
Externí odkaz: